121 related articles for article (PubMed ID: 11136835)
1. Scientists recall progress and promise of translational research.
Marwick C
J Natl Cancer Inst; 2001 Jan; 93(1):13-5. PubMed ID: 11136835
[No Abstract] [Full Text] [Related]
2. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
[No Abstract] [Full Text] [Related]
3. Clinical advances in therapies targeting the interleukin-2 receptor.
Church AC
QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007
[No Abstract] [Full Text] [Related]
4. Treatment of recurrent hepatitis C after liver transplantation with IL-2r Ab.
Pinna AD; Ricordi C; Weppler D; Ruiz P; Tzakis AG
Transplant Proc; 2001; 33(1-2):1087-9. PubMed ID: 11267203
[No Abstract] [Full Text] [Related]
5. Anti-CD25 therapy impairs donor-specific Th1 and Th2 cytokine-producing peripheral blood cells after clinical heart transplantation.
van Besouw NM; Balk AH; van Vliet M; van der Meide PH; Maat AP; van Gelder T; Baan CC; Weimar W
Transplant Proc; 2002 Nov; 34(7):2942-3. PubMed ID: 12431667
[No Abstract] [Full Text] [Related]
6. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA
J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
[TBL] [Abstract][Full Text] [Related]
7. The role of interleukin-2 receptor alpha in cancer.
Kuhn DJ; Dou QP
Front Biosci; 2005 May; 10():1462-74. PubMed ID: 15769637
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody approved for renal transplants.
Am J Health Syst Pharm; 1998 Feb; 55(3):207-8. PubMed ID: 9492247
[No Abstract] [Full Text] [Related]
9. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
Osborne GE; Pagliuca A; Ho A; du Vivier AW
Br J Dermatol; 2006 Sep; 155(3):617-20. PubMed ID: 16911291
[TBL] [Abstract][Full Text] [Related]
10. Treatment of recalcitrant psoriasis with daclizumab.
Wohlrab J; Fischer M; Taube KM; Marsch WC
Br J Dermatol; 2001 Jan; 144(1):209-10. PubMed ID: 11167723
[No Abstract] [Full Text] [Related]
11. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab for the treatment of relapsing-remitting multiple sclerosis.
Herwerth M; Hemmer B
Expert Opin Biol Ther; 2017 Jun; 17(6):747-753. PubMed ID: 28286970
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab to prevent acute rejection in renal transplantation.
Abramowicz D
N Engl J Med; 1998 Jun; 338(23):1700-1. PubMed ID: 9616069
[No Abstract] [Full Text] [Related]
14. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
van de Linde P; Vd Boog PJ; Tysma OM; Elliott JF; Roelen DL; Claas FH; de Fijter JW; Roep BO
Clin Exp Immunol; 2007 Jul; 149(1):56-62. PubMed ID: 17459076
[TBL] [Abstract][Full Text] [Related]
15. Therapy with immunoglobulin: applications for monoclonal antibodies.
Stowell CP
J Infus Nurs; 2006; 29(3 Suppl):S29-44. PubMed ID: 16878853
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies.
Kircher B; Lätzer K; Gastl G; Nachbaur D
Clin Exp Immunol; 2003 Dec; 134(3):426-30. PubMed ID: 14632747
[TBL] [Abstract][Full Text] [Related]
17. Dual purpose: some cancer therapies used to treat autoimmune diseases.
Ben-Ari ET
J Natl Cancer Inst; 2004 Apr; 96(8):577-9. PubMed ID: 15100330
[No Abstract] [Full Text] [Related]
18. Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.
Tomaske M; Amon O; Bosk A; Handgretinger R; Schneider EM; Niethammer D
Med Pediatr Oncol; 2002 Feb; 38(2):141-2. PubMed ID: 11813188
[No Abstract] [Full Text] [Related]
19. Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation.
Papagoras D; Papalois A; Tsaroucha A; Lytras D; Kyriazanos J; Giannakou N; Laftsidis P; Simopoulos C
World J Gastroenterol; 2007 Mar; 13(9):1435-7. PubMed ID: 17457977
[TBL] [Abstract][Full Text] [Related]
20. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab.
Egan CA; Brown M; White JD; Yancey KB
Clin Immunol; 2001 Nov; 101(2):146-51. PubMed ID: 11683573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
